CLAIMS

1. Use of a compound deutetrabenazine or a composition comprising said compound in the manufacture of a medicament for treating abnormal involuntary movement in a subject in need thereof wherein the medicament is to be administered at a daily dosage of at least about 6 mg per day.
2. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 1 wherein the daily dosage of at least about 6 mg per day is increased by 6 mg per day to a subsequent daily dosage if the abnormal involuntary movement is not reduced and the daily dosage is tolerable.
3. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 1 wherein if any subsequent daily dosage is not tolerated, the daily dosage is decreased by at least 6 mg per day to a subsequent daily dosage.
4. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 1 wherein the medicament is to be administered after discontinuing the administration of a daily dosage of tetrabenazine in the subject.
5. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 4 wherein the daily dosage thereof at least about 6 mg per day is about 30 to 70% of the total daily dosage of tetrabenazine administered in the subject.
6. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 5 wherein the daily dosage of at least about 6 mg per day is increased by 6 mg per day to a subsequent daily dosage if the degree of control of the abnormal involuntary movement is comparable to the control when the subject was receiving tetrabenazine.
7. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 5 wherein if any subsequent daily dosage is not tolerated, the daily dosage is decreased by at least 6 mg per day to another subsequent daily dosage.
8. Use of a compound deutetrabenazine or a composition comprising said compound in the manufacture of a medicament for treating a movement disorder in a subject in need thereof wherein the medicament is to be administered at a daily dosage of about 6 mg to 78 mg.
9. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 8 wherein said treatment has any one or more of the following effects: reduces chorea in the subject by at least 10%, improves subject's physical functioning, swallowing, balance, and motor function by at least 10%, wherein said treatment causes no significant increase in insomnia, depression, anxiety, agitation, suicidal ideation, akathisia, irritability, fatigue, parkinsonism or dysphagia, and wherein the maximal increases in QTcF is less than 5 ms.
10. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 8 wherein said treatment has any one or more of the following effects: reduces chorea in the subject by at least 10%, improves subject's physical functioning, swallowing, and balance, wherein said treatment causes no significant increase in insomnia,

depression, anxiety, agitation, suicidal ideation, akathisia, irritability, fatigue, parkinsonism or dysphagia, and wherein the maximal increases in QTcF is less than 5 ms.

11. Use of a compound deutetrabenazine or a composition comprising said compound in the manufacture of a medicament for treating abnormal involuntary movement in a subject in need thereof wherein the medicament is to be administered with a daily dosage of deutetrabenazine which reduces the subject's abnormal involuntary movement and which improves one or more of the following subject's symptoms: depression, insomnia, somnolence, fatigue, dizziness, restlessness, agitation, akathisia, parkinsonism, nausea, anxiety, impaired swallowing, body weight gain, irritability, and compulsive behaviour.
12. Use of a compound deutetrabenazine or a composition comprising said compound in the manufacture of a medicament for treating Huntington's disease in a subject in need thereof.
13. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 12 wherein said treatment reduces chorea and improves motor function in the subject.
14. Use of a compound deutetrabenazine or a composition comprising said compound in the manufacture of a medicament for treating tardive dyskinesia, or Tourette syndrome in a subject in need thereof.
15. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 14 wherein said treatment reduces motor or phonic tics in the subject with Tourette syndrome.
16. The use of the compound deutetrabenazine or the composition comprising said compound according to Claim 15 wherein said treatment reduces tic severity in the subject with Tourette syndrome as measured by the subject's Tourette Syndrome Patient Global Impression of Severity (TS-PGIS).
17. Use of a compound deutetrabenazine or a composition comprising said compound in the manufacture of a medicament for treating a movement disorder wherein a therapeutically effective amount of the medicament is to be administered for a period of time sufficient to achieve one or more of these effects: reduces the following: chorea by at least 10%, abnormal involuntary movements in the subject with tardive dyskinesia, motor tics, vocal or phonic tics, motor and vocal or phonic tics, impairment in the subject with Tourette Syndrome, severity of Tourette syndrome, patient global impression of severity in the subject with Tourette Syndrome, and improves the following: motor function by at least 10%, physical functioning, swallowing, balance, and the subject's patient of clinical global impression of change.